> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Breakthrough Designation for Seattle Genetics Adcetris
- URL: https://www.fdaweb.com/breakthrough-designation-for-seattle-genetics-adcetris/
- Published: 2018-11-15T12:00:00.000Z
- Updated: 2026-09-15T00:45:01.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142832

FDA has granted Seattle Genetics a breakthrough therapy designation for Adcetris (brentuximab vedotin) for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with CHP (cyclophosphamide, doxorubicin, and prednisone). The designation was granted based on data from the Phase 3 ECHELON-2 clinical trial, according to the company. Adcetris is an antibody-drug conjugate directed to CD30, which is expressed on the surface of several types of PTCL, it says.